biotech / news / / Benzinga
Eli Lilly and Co. shares were little changed in Monday's premarket session.
Eli Lilly's Jaypirca combined with venetoclax and rituximab significantly improved progression-free survival in CLL/SLL.
KEY POINTS
- The BRUIN CLL-322 trial marks Jaypirca's fourth positive Phase 3 study, supporting potential label expansion this year.
- Jaypirca showed non-inferiority and numerically higher response rates versus Imbruvica in the BRUIN CLL-314 trial.
- Retevmo's Phase 3 LIBRETTO-432 trial showed significant event-free survival improvement in early-stage lung cancer patients.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →